Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of agents targeting checkpoint blockade continues to transform the treatment paradigm for many oncology indications at an incredible rate. This Special Topics report provides a comprehensive market forecast of current and emerging immune checkpoint inhibitors and analyzes the market trends and dynamics in a range of oncology indications.


  • What is the current landscape for approved immune checkpoint inhibitors? What are the trends in each indication?
  • How will emerging immune checkpoint inhibitors be positioned in the market? How will the indication-specific market trends and dynamics evolve?
  • What is the commercial potential of current and emerging immune checkpoint inhibitors by brand, indication, combination type, and geography? How will the market evolve over the 2019-2029 forecast period?


United States, EU5, Japan.


Drug-treated patient populations by brand, indication, combination type, and geography for indications for which immune checkpoint inhibitors are approved or forecast for approval.


10-year, annualized, drug-level sales of immune checkpoint inhibitors through 2029, segmented by indication, combination type, and geography.


Currently approved agents targeting PD-1, PD-L1, and CTLA-4.


Phase III/PR.


DRG’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in relevant oncology indications.

Table of contents

  • Immune Checkpoint Inhibitors - Special Topics - Special Topics (G7)
    • Special Topics Immune Checkpoint Inhibitors, US, EU5, Japan December 2020

Author(s): Paul Wilcock, PhD; Fiona Wiegert; Laura Vinuesa, DVM, MSc

Since October 2015, Dr. Wilcock has been a Business Insights Analyst in the oncology team at Decision Resources Group. He has experience in various indications including metastatic malignant melanoma and renal cell carcinoma, and will have a major focus on gastric cancer going forward.

Previously, Dr. Wilcock was a Research Funding Manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He gained his doctorate from the University of Manchester where he utilized Systems Biology to explore the role of cell signaling and hypoxia in oral cancer.

Laura Vinuesa, DVM, M.Sc., is a Senior Business Insights Analyst in the Oncology Division at Decision Resources Group, with expertise in thyroid carcinoma and bladder cancer. Previously, Dr. Vinuesa was an EU Market Access Analyst in the Global Market Access Insights Team at Decision Resources Group. She has expertise in market access, pricing and reimbursement, health technology assessment, and health policy.

Prior to joining Decision Resources, she worked as Market Access & Institutional Relations Analyst at Pfizer in Spain, providing support for the successful market launch of drugs for different areas: cardiovascular, oncology, mental disorder and rare disease. She is a Doctor of Veterinary Medicine from the Complutense University of Madrid, and holds a M.Sc. in Clinical Research and Pharmaceutical Medicine from EPHOS - School of PharmaStudies.